Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin
Authors: Kesara Na-Bangchang
P. Tippawangkosol
A. Thanavibul
R. Ubalee
J. Karbwang
Mahidol University
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 12-Aug-1999
Citation: International Journal of Clinical Pharmacology Research. Vol.19, No.1 (1999), 9-17
Abstract: Pharmacokinetic and pharmacodynamic interactions between dihydroartemisinin and mefloquine were investigated in 10 healthy Thai males. The study was of a three-way crossover design. Subjects were randomized to receive three drug regimens on three separate occasions as follows: regimen I: a single oral dose of 300 mg dihydroartemisinin; regimen II: a single oral dose of 750 mg mefloquine, regimen III: a single oral dose of 300 mg dihydroartemisinin, given concurrently with a single oral dose of 750 mg mefloquine. All regimens were well tolerated. Oral dihydroartemisinin was rapidly absorbed and disappeared from systemic circulation within 8-10 h. Mefloquine absorption and disposition were relatively slow processes. Pharmacokinetics of dihydroartemisinin and mefloquine when given concurrently were similar except for the absorption rate of mefloquine which was faster in the presence of dihydroartemisinin. Pharmacodynamically, the combination of dihydroartemisinin and mefloquine resulted in a synergistic effect on ex vivo blood schizontocidal activity. Maximum activity (A(max)) and area under effect-time curve (AUEC) of dihydroartemisinin and mefloquine were increased approximately two- and 20-fold (A(max)), and four- and twofold respectively compared with each individual drug alone. AUEC of mefloquine during the first 24 h (AUEC(0-24h)) was increased approximately 50-fold in the presence of dihydroartemisinin.
ISSN: 02511649
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.